Friday, 27 May 2022

Australia's most trusted
source of pharma news

Friday, 27 May 2022

Early re-entry does the trick

Posted 23 August 2021 AM

Four out of five PBAC submissions that used the early re-entry pathway won a positive recommendation and the fifth has been deferred - results that suggest the new system could be working. 

Outcomes from the July meeting included positive recommendations for Bayer's Nubeqa for castration resistant carcinoma of the prostate, Otsuka's Inqovi for high risk myelodysplastic syndromes and chronic myelomonocytic leukaemia, STA's Qinlock for gastrointestinal stromal tumour and AbbVie's Venclexta for acute myeloid leukaemia.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (9)

Sales & Customer Relations (38)

Access & Reimbursement (4)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (2)

Other (28)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.